Glaucoma

Peer and public reviews for Care of the Patient with Primary Open-Angle Glaucoma will be taken until April 24.

LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens created by the company’s proprietary 3D printing technology.

Switching produced an additional 25% IOP reduction in mild-to-moderate OAG and OHT.

Findings from Mass Eye and Ear’s collaborative study provides new insights regarding gene expression and post-transcriptional gene regulation.

Oluwatosin U Smith, MD, urges consideration of the interaction between corneal and glaucomatous disease whenever treating glaucoma or corneal issues during the annual Glaucoma 360 meeting in San Francisco, California.

Pairing the patient with the right therapy can yield dramatic results.

Robert L Stamper, MD, raises the question of physician liability for allowing the patient to drive.

In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.

Retinal imaging and genetics data was used to predict future disease risk in a recent study.

The new contact lenses contain micro-sensors which monitor changes in IOP over a period of several hours, sending the data collected wirelessly so it can be analyzed by an eye care provider and a diagnosis given.

Recent research gives clinicians another reason to encourage cessation.

The eye care company and nonprofit organization are teaming up to provide educational resources, patient stories, and a fundraising challenge to help find a cure for glaucoma.

Available information includes a new promotional toolkit for The Glaucoma Community, glaucoma patient testimonial, and medical expert interview videos.

iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has received FDA approval following a new drug application (NDA) submission.

Earlier this year, Aurion’s cell therapy received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for the management of bullous keratopathy, marking the first regulatory approval in the world for an allogeneic cell therapy to manage corneal endothelial disease.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

Myopia as a glaucoma risk factor, and high myopia as a potential glaucoma mimicker, can be quite the clinical headache

As new treatment options continue to enter the glaucoma space, clinicians can provide the best care to each individual patient.

Patients with HTG had significantly fewer mtDNA copies per nuclear DNA.

Don’t forget to look at a patient’s optic nerve through a dilated pupil.

Evaluating images for quality, artifacts, and segmentation errors.

With this new funding, Smartlens gives the possibility of new treatment for glaucoma with miLens.

The financing will help advance the company’s novel treatment system for glaucoma and other chronic ophthalmic diseases.

Procedures in the pipeline hold greater appeal for cataract and refractive surgeons, patients.

The Laroche Glaucoma Risk Calculator is a valuable tool for glaucoma screenings both in the community and in optometrist offices.

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego where he shared insights from his presentation comparing patient results of the Hydrus stent and the iStent inject W with or without ABiC (or ab-interno canaloplasty).

Diagnostic test results may vary in the same patient on the same day.